Source:http://linkedlifedata.com/resource/pubmed/id/11248482
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0006901,
umls-concept:C0008555,
umls-concept:C0025663,
umls-concept:C0031327,
umls-concept:C0032105,
umls-concept:C0034693,
umls-concept:C0034721,
umls-concept:C0185115,
umls-concept:C0185125,
umls-concept:C0870883,
umls-concept:C1280551,
umls-concept:C1314934,
umls-concept:C1314935,
umls-concept:C1519941
|
pubmed:issue |
5-6
|
pubmed:dateCreated |
2001-3-15
|
pubmed:abstractText |
E-6006, 5-(alpha-[2-(dimethylamino)ethoxy]-2-thienylmethyl)-1-methyl-1H-pyrazole is a new antidepressive compound and E-6332, 5-(alpha-[2-(methylamino)ethoxy]-2-thienylmethyl)-1-methyl-1H-pyrazole is its desmethylate metabolite. With the aim of quantifying E-6006 and E-6332, simultaneously in rat or dog plasma, a method of analysis based on solid-phase extraction coupled with capillary gas chromatographic system with N-P detection was developed and validated. E-6006, E-6332 and its internal standard (E-4018) were isolated from plasma using an off-line semiautomatic solid-phase extraction method. Gas chromatography separations were carried out by means of 12 m length, 0 2 mm (i.d.) and 0.33 microm (f.t.) ULTRA 1 type capillary column in splitless mode of injection at 190 degrees C, with a TSD or specific nitrogen--phosphorus detector. No peaks interfering with the quantification of E-6332 and E-6006 were observed. The limit of quantification was 5 ng/ml with a precision and accuracy <17%. The peak height ratios were proportional to E-6332 and E-6006 concentration over the range from 5 to 600 ng/ml (r(2)>0.998). Mean recoveries of E-6332, E-6006 and internal standard from rat plasma were between 57.1 and 82.6. Intra-assay precision coefficients were <8.0 and <11.8%, respectively, for E-6332 and E-6006, with an accuracy <12.6 and <9.7%. Both inter-assay precision and accuracy were within acceptable limits (<15%). In dog, the results were very similar to those obtained in rat. To show an example of the suitability of the method to determine E-6332 and E-6006, plasma profiles obtained after single oral and intravenous administration of 20 mg/kg to rats and 25 mg/kg to dogs are reported.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0731-7085
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
24
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
887-96
|
pubmed:dateRevised |
2003-11-14
|
pubmed:meshHeading |
pubmed-meshheading:11248482-Animals,
pubmed-meshheading:11248482-Antidepressive Agents,
pubmed-meshheading:11248482-Chromatography, Gas,
pubmed-meshheading:11248482-Dogs,
pubmed-meshheading:11248482-Pyrazoles,
pubmed-meshheading:11248482-Rats,
pubmed-meshheading:11248482-Reference Standards,
pubmed-meshheading:11248482-Sensitivity and Specificity
|
pubmed:year |
2001
|
pubmed:articleTitle |
Validation of a chromatographic method to determine E-6006 and its metabolite E-6332 in rat and dog plasma by solid-phase extraction and capillary gas chromatography. Application in pharmacokinetics.
|
pubmed:affiliation |
Department of Pharmacokinetics and Metabolism, Laboratorios Dr. Esteve, S.A. Av. Mare de Déu de Montserrat 221, 08041 Barcelona, Spain. spuig@esteve.es
|
pubmed:publicationType |
Journal Article,
Validation Studies
|